Group 1 - The company, Luoxin Pharmaceutical, reported that as of January 30, 2026, the total number of shareholders is 37,496 [2]

Core Viewpoint - The company, Luoxin Pharmaceutical Group Co., Ltd., anticipates a negative net profit for the fiscal year 2025, despite improvements in operational performance and a significant reduction in losses compared to the previous year [2][5]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025, with an expected net profit in negative territory [1]. - The financial data related to this performance forecast has not been audited by the accounting firm, but preliminary discussions have taken place without any disagreements [2]. Group 2: Reasons for Performance Changes - The company continues to strategically focus on the pharmaceutical industry, particularly in the gastrointestinal field, with significant growth driven by its core innovative drug, Tegoprazan (brand name: Taixinzan) [3]. - The commercialization of Tegoprazan has progressed well, with new indications for "duodenal ulcers" and "eradication of Helicobacter pylori in conjunction with appropriate antibiotic therapy" added to the medical insurance directory, which is expected to enhance sales and operational efficiency [4]. Group 3: Overall Business Condition - The overall business condition for 2025 shows a positive improvement trend, with a significant reduction in losses year-on-year, primarily due to the successful commercialization of Tegoprazan and the diminishing negative impact from previous asset impairments [4]. - The company has recognized fair value losses related to financial liabilities from its investment in Shangyao Luoxin, which is a non-recurring loss, and the impact is expected to be one-time as the performance guarantee period has ended [5]. - The company has initiated procedures to dispose of loss-making businesses related to LeKang Pharmaceutical and Luoxin Anruo Weita, which will further reduce losses once completed [5].

Core Viewpoint - Luoxin Pharmaceutical (002793.SZ) forecasts a net loss of 250 million to 340 million yuan for the year 2025, compared to a loss of 965.4962 million yuan in the previous year [1] Financial Performance - The company anticipates a non-GAAP net loss of 260 million to 350 million yuan for 2025, compared to a loss of 768.1208 million yuan in the same period last year [1] Strategic Focus - In 2025, the company will continue to strategically focus on the pharmaceutical manufacturing sector, particularly in the advantageous digestive system field [1] - The growth of the company's core innovative drug, Tegoprazan (brand name: Taixinzan®), is expected to drive improvements in product structure and growth quality [1]

每经头条（nbdtoutiao）——中国无人驾驶"军团"，"武装"阿布扎比 每经AI快讯，罗欣药业1月30日晚间发布业绩预告，预计2025年归属于上市公司股东的净利润-34000万 元至-25000万元，上年同期归属于上市公司股东的净利润-96549.62万元。 （记者 张明双） ...

Financial Projections - The estimated net profit for 2025 is projected to be between -34,000 and -25,000 thousand yuan, compared to -96,549.62 thousand yuan in the same period last year [4]. - The estimated net profit after deducting non-recurring gains and losses is projected to be between -35,000 and -26,000 thousand yuan, compared to -76,812.08 thousand yuan in the same period last year [4]. - The basic earnings per share is expected to be between -0.3300 and -0.2300 yuan, compared to -0.9058 yuan in the same period last year [4]. Business Strategy and Growth - The company continues to strategically focus on the pharmaceutical industry, particularly in the digestive system field, with significant growth driven by the core innovative drug Tegoprazan [6]. - The commercial progress of Tegoprazan has been strong, with new indications added to the medical insurance directory, which is expected to enhance sales scale and operational efficiency [7]. Asset Management and Losses - The negative impact from impairment losses related to long-term assets of subsidiaries has significantly decreased in 2025 compared to 2024 [7]. - The company has initiated disposal procedures for loss-making businesses, which are expected to reduce the impact of losses once completed [8]. - The company has confirmed fair value losses related to financial liabilities from its investment in Shangyao Luoxin, which will be audited for final amounts [7]. Financial Data Caution - The company warns that the financial data presented is preliminary and subject to final audit by the accounting firm [9]. - Investors are advised to make cautious decisions and be aware of investment risks due to the preliminary nature of the financial estimates [9].

Core Viewpoint - The company, Luoxin Pharmaceutical (002793.SZ), held its first employee representative meeting on January 29, 2026, to elect Mr. Ma Shaohong as the employee representative director for the sixth board of directors, marking a significant governance update for the company [1]. Group 1 - The employee representative director will serve alongside the directors elected by the shareholders, forming the sixth board of directors [1]. - The term for the newly elected board members is three years, starting from the approval date of the employee representative meeting until the end of the sixth board's term [1].

Group 1 - The company, Luoxin Pharmaceutical, held its sixth first board meeting on January 29, 2026, in two locations: Linyi High-tech Industrial Development Zone and Shanghai's Pudong New Area [1] - The meeting reviewed the proposal regarding the appointment of the board secretary among other documents [1] Group 2 - The investigation into the "Jie Wo Rui" redemption crisis on the Shuibei Gold platform revealed a 40-fold leverage bet, indicating that the platform incurs losses as gold prices rise [1] - The platform's owner claims to still be in Shenzhen, while investors express dissatisfaction with the proposed redemption plan, which offers only 20% of the principal [1]

罗欣药业集团股份有限公司董事会 2026 年 1 月 29 日 证券代码：002793 股票简称：罗欣药业 公告编号：2026-011 罗欣药业集团股份有限公司 关于选举第六届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 罗欣药业集团股份有限公司（以下简称"公司"）第五届董事会任期将于 2026 年 1 月 30 日届满，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《罗欣药业集团股份有限公司章程》（以下简称"《公司章程》"）等有关规定， 公司进行董事会换届选举。公司于 2026 年 1 月 29 日召开了 2026 年第一次职工 代表大会，选举马少红先生为公司第六届董事会职工代表董事（简历见附件）， 本次职工代表大会推选产生的职工代表董事将与公司股东会选举产生的董事会 成员共同组成公司第六届董事会，任期三年，自本次职工代表大会审议通过之日 起至公司第六届董事会任期届满之日止。 马少红先生符合《公司法》《公司章程》和《董事会议事规则》中有关董事 任职资格和条件的规定。本次选举完成后，董事会中兼任公司高级管理人员及由 职工 ...

证券代码：002793 股票简称：罗欣药业 公告编号：2026-010 罗欣药业集团股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 3.现场会议召开时间：2026年1月29日（星期四）下午2:00； 4.现场会议召开地点：上海市浦东新区东育路255弄4号前滩世贸中心一期A 栋7层会议室； 5.网络投票时间： （1）通过深圳证券交易所交易系统进行网络投票的具体时间为2026年1月29 日的交易时间，即9:15-9:25，9:30-11:30和13:00-15:00； （2）通过深圳证券交易所互联网投票系统进行网络投票的开始时间为2026 年1月29日上午9:15，结束时间为2026年1月29日下午3:00。 特别提示： 1.本次股东会未出现否决提案的情况； 2.本次会议未涉及变更以往股东会已通过的决议的情况。 一、会议召开基本情况 1.会议召集人：罗欣药业集团股份有限公司（以下简称"公司"）董事会； 2.会议主持人：公司董事长刘振腾先生； 6.召开方式：现场会议与网络投票相结合的方式。 7.本次股东会的召集和 ...

北京市金杜律师事务所上海分所 关于罗欣药业集团股份有限公司 2026 年第一次临时股东会 之法律意见书 致：罗欣药业集团股份有限公司 在本法律意见书中，本所仅对本次股东会召集和召开的程序、出席本次股 东会人员资格和召集人资格及表决程序、表决结果是否符合有关法律、行政法 规、《股东会规则》和《公司章程》的规定发表意见，并不对本次股东会所审议 的议案内容以及该等议案所表述的事实或数据的真实性和准确性发表意见。本 所仅根据现行有效的中国境内法律法规发表意见，并不根据任何中国境外法律 发表意见。 本所依据上述法律、行政法规、规章及规范性文件和《公司章程》的有关 规定以及本法律意见书出具日以前已经发生或者存在的事实，严格履行了法定 职责，遵循了勤勉尽责和诚实信用原则，对公司本次股东会相关事项进行了充 分的核查验证，保证本法律意见书所认定的事实真实、准确、完整，本法律意 见书所发表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大 遗漏，并承担相应法律责任。 本所同意将本法律意见书作为本次股东会的公告材料，随同其他会议文件 一并报送有关机构并公告。除此以外，未经本所同意，本法律意见书不得为任 何其他人用于任何其他 ...